CAS: 9005-49-6; Heparin

该化合物是一种天然的抗凝胶,在防止血块形成方面起着关键作用.这是一种甘蓝氨基甘油,一种由重复的沙酸单位组成的聚沙酸,包括泌酸和氨基糖.Heparin主要从动物组织中提取,特别是从猪的肠道粘膜或牛肺中提取.其结构特征是高程度的硫化,导致其负电荷,并加强其与各种蛋白质的相互作用,包括抗血清三,导致其抗凝胶效应.Heparin通常用于临床环境中预防和治疗血栓病,如深血栓和肺栓塞.通过注射进行,因为口服这种物质吸收不良.人们还知道这种物质具有潜在的副作用,包括出血并发症和肝素诱导的血栓塞.

结构式图片

欧盟法规

C&L通报REACH预注册

上下游产品

heparin sodium salt 12H20O17S2C12H20O17S2 12H20O17S2C12H20O17S2 12H20O14SC12H20O14S

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-6576447-B2
    优先权日:2000-03-21
    标 题:Method for synthesis of nucleic acids
    发明人:TONOIKE HIROSHI
    权利人:SHIMADZU CORP
    摘要:An object of the present invention is to provide a novel method for suppressing the action of nucleic acid synthesis inhibitory substances and thereby amplifying a nucleic acid in a sample efficiently.According to the present invention, in a method for synthesis of nucleic acids to amplify an intended nucleic acid in a sample, the sample is brought in advance into contact with an insoluble polymer of a polyanion, a sulfated polymer or a sulfated polysaccharide, to remove nucleic acid synthesis inhibitory substances.

    专利号:US-6156547-A
    优先权日:1990-04-16
    标 题:Apparatus for the synthesis of saccharide compositions
    发明人:ROTH STEPHEN
    权利人:NEOSE PHARM INC
    摘要:This invention relates to an apparatus containing specific binary combinations of glycosyltransferases, for the synthesis of specific saccharide compositions such as, for example, oligosaccharides, polysaccharides, glycolipids, and glycopeptides.

    专利号:US-6846917-B2
    优先权日:2001-01-23
    标题:Solid- and solution-phase synthesis of heparin and other glycosaminoglycans
    发明人:SEEBERGER PETER H; ORGUEIRA HERNAN; SCHELL PETER
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

    专利号:US-9034624-B2
    优先权日:2009-06-16
    标 题 :Process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules, polymeric conjugates and relative uses thereof
    发明人:D ESTE MATTEO; RENIER DAVIDE; PASUT GIANFRANCO; ROSATO ANTONIO
    权利人:D ESTE MATTEO; RENIER DAVIDE; PASUT GIANFRANCO; ROSATO ANTONIO; FIDIA FARMACEUTICI
    摘要:The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. n An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.

    专利号:US-4818816-A
    优先权日:1981-04-28
    标 题:Process for the organic synthesis of oligosaccharides and derivatives thereof
    发明人:PETITOU MAURICE; JACQUINET JEAN-CLAUDE; SINAY PIERRE; CHOAY JEAN; LORMEAU JEAN-CLAUDE; NASSR MAHMOUD
    权利人:CHOAY SA
    摘要:The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compounds constituted or terminated by units of glucosamine structure and of uronic acid structure respectively, said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained.

    专利号:US-7655445-B2
    优先权日:2003-11-12
    标题 :Methods for synthesis of sulfated saccharides
    发明人:ROSENBERG ROBERT D; BALAGURUNATHAN KUBERAN
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:The present invention provides methods, processes and reaction mixtures, which produce sulfated heparosan polysaccharides. This invention also provides methods and reaction mixtures for the synthesis of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Erickson M, Hiebert LM, Carr AP, Stickney JD. Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs. Can J Vet Res. 2014 Jul;78(3):193-201.
    2: Barrowcliffe TW. History of heparin. Handb Exp Pharmacol. 2012;(207):3-22. doi: 10.1007/978-3-642-23056-1_1. doi: 10.1111/jth.13555. Epub 2016 Dec 16. doi: 10.1016/j.carres.2014.06.023. Epub 2014 Jul 3. Review. doi: 10.1038/ki.2013.152. Epub 2013 May 15. Review. doi: 10.3892/ijo.2014.2803. Epub 2014 Dec 19. doi: 10.1097/NUR.0b013e3182a0ba2b. Review. doi: 10.1016/j.critrevonc.2013.06.007. Epub 2013 Jul 12. Review. doi: 10.1016/j.coms.2016.06.008. Epub 2016 Sep 10. Review. Review. doi: 10.1016/j.jpba.2013.06.033. Epub 2013 Jul 16. doi: 10.1016/j.ijcard.2014.09.105. Epub 2014 Sep 30. Review. doi: 10.1016/j.biopha.2016.02.021. Epub 2016 Mar 9. doi: 10.5507/bp.2016.042. Epub 2016 Sep 19. doi: 10.4155/fmc.11.185. Review.
    18: Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest. 2011 Aug;140(2):374-381. doi: 10.1378/chest.10-3084. Epub 2011 Feb 24. Erratum in: Chest. 2015 Nov;148(5):1363. doi: 10.1016/S0167-5273(16)12004-2. Review. doi: 10.1007/s00404-012-2558-1. Epub 2012 Sep 18.

    合成参考文献


    摘要:Australian and New Zealand Journal of Medicine., 28(59), 1998 []
    摘要:Southern Medical Journal., 80(1450), 1987 []
    参考文献:10.1007/s11739-012-0883-9
    摘要:Khorana AA. Targeted prophylaxis in cancer: the evidence accumulates. Internal and Emergency Medicine. 2012 Dec 27;8(3):187–9. doi: 10.1007/s11739-012-0883-9.
    参考文献:10.1097/00001721-199611000-00007
    摘要:de Raucourt E, Vinsonneau C, Juvin K, Fischer AM, Meyer G. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. Blood Coagul Fibrinolysis. 1996 Nov;7(8):786–8. doi: 10.1097/00001721-199611000-00007.
    参考文献:10.1002/clc.4950250704
    摘要:Shapira Y, Sagie A, Battler A. Low‐molecular‐weight heparin for the treatment of patients with mechanical heart valves. Clinical Cardiology. 2002 Jul;25(7):323–7. doi: 10.1002/clc.4950250704.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知